WATERTOWN, Mass., April 15, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH) today announced eight data presentations at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 25-28 in Copenhagen, Denmark. Presentations will include results from the Company's phase 3 IGNITE program for its lead drug candidate, eravacycline, as well as data from its preclinical pipeline programs.
The details for the data presentations at ECCMID are as follows:
Eravacycline presentations:
Late Breaker Oral Session: Results of IGNITE1: A phase 3 study to evaluate the efficacy and safety of eravacycline versus ertapenem in complicated intra-abdominal infections
Date and time: Tuesday, April 28 at 12:06 pm CEDT
Location: Hall E
Abstract number: 4174
Session info: Late-breaker – results from latest clinical trials
Oral session: Results of the lead-in study on the safety and efficacy of eravacycline versus levofloxacin in complicated urinary tract infections (cUTI)
Date and time: Monday, April 27 at 5:24 pm CEDT
Location: Hall J
Abstract number: O198
Session info: New antibacterial agents – phase 2 and phase 3 clinical trials
Pipeline program presentations:
Poster title: TP-076 is active in vitro against biofilms formed by a panel containing fluoroquinolone-resistant and susceptible uropathogenic Escherichia coli clinical isolates
Date and time: Saturday, April 25 from 3:30 – 4:30 pm CEDT
Location: Poster Area
Poster number: P0054
Session info: Issues in prevention and management of biofilm and foreign-body infection
Poster title: In vitro activities of novel tetracyclines against molecularly characterized carbapenem-resistant Gram-negative pathogens
Date and time: Saturday, April 25 from 3:30 – 4:30 pm CEDT
Location: Poster Area
Poster number: P0243
Session info: New antibacterial drugs
Poster title: Efficacy evaluation of TP-271, a novel fluorocycline, in a neutropenic murine pneumonia model against susceptible and resistant Gram-positive pathogens
Date and time: Saturday, April 25 from 3:30 – 4:30 pm CEDT
Location: Poster Area
Poster number: P0244
Session info: New antibacterial drugs
Poster title: Identification of Klebsiella pneumoniae genes involved in tigecycline-resistance using transposon mutagenesis
Date and time: Monday, April 27 from 1:30 – 2:30 pm CEDT
Location: Poster Area
Poster number: P1022
Session info: Assaying and explaining multidrug resistance in Gram-negative bacteria
Tetraphase sponsored research relating to the prevalence of multidrug-resistant (MDR) Acinetobacter baumannii, a pathogen considered an urgent threat by the U.S. Centers for Disease Control and Prevention (CDC):
ePoster title: Secular trends in Acinetobacter baumannii resistance in pneumonia and bacteraemia in the US, 2003-2012: a survey study
Date and time: Saturday, April 25
Location: ePoster Viewing Area
Poster number: EV0255
Session info: Antimicrobials: resistance surveillance
ePoster title: Acinetobacter baumannii recovered from nursing home patients with pneumonia and/or bacteraemia carries a high risk of antimicrobial resistance: a survey study
Date and time: Saturday, April 25
Location: ePoster Viewing Area
Poster number: EV0256
Session info: Antimicrobials: resistance surveillance
Full abstracts can be found on the ECCMID website at http://www.eccmid.org/.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). This program includes two phase 3 clinical trials: IGNITE1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE2 for the indication of complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. In addition to eravacycline, Tetraphase's pipeline includes TP-271 and TP-6076, preclinical antibiotic candidates that are currently being evaluated for clinical suitability. Please visit www.tphase.com for more company information.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether results obtained in preclinical studies and early or interim clinical trials will be indicative of results obtained in future clinical trials; whether eravacycline will advance through the clinical trial process on a timely basis; whether the results of the Company's trials will warrant regulatory submission and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if eravacycline obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our annual report on Form 10-K, filed with the Securities and Exchange Commission on March 6, 2015. In addition, the forward-looking statements included in this press release represent our views as of April 15, 2015. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.